Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS – Research Report), Aclaris Therapeutics (ACRS – Research Report) and Quanterix (QTRX – Research Report).
Xeris Pharmaceuticals (XERS)
In a report issued on January 11, Roanna Ruiz from Leerink Partners reiterated a Buy rating on Xeris Pharmaceuticals. The company’s shares closed last Friday at $2.77, close to its 52-week high of $3.07.
According to TipRanks.com, Ruiz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $20.17 average price target, a 588.4% upside from current levels. In a report issued on January 4, Craig-Hallum also maintained a Buy rating on the stock with a $51.00 price target.
See the top stocks recommended by analysts >>
Aclaris Therapeutics (ACRS)
In a report issued on January 10, Thomas Smith from Leerink Partners reiterated a Hold rating on Aclaris Therapeutics. The company’s shares closed last Friday at $0.92, close to its 52-week low of $0.59.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Currently, the analyst consensus on Aclaris Therapeutics is a Hold with an average price target of $3.25, which is a 242.1% upside from current levels. In a report issued on January 10, Jefferies also downgraded the stock to Hold with a $1.00 price target.
Quanterix (QTRX)
Leerink Partners analyst Puneet Souda maintained a Buy rating on Quanterix on January 10. The company’s shares closed last Friday at $22.91.
According to TipRanks.com, Souda ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Quanterix has an analyst consensus of Strong Buy, with a price target consensus of $31.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XERS:
